Literature DB >> 2215578

Plasma prorenin activity and complications in children with insulin-dependent diabetes mellitus.

D M Wilson1, J A Luetscher.   

Abstract

BACKGROUND: Renin, secreted into the blood by the juxtaglomerular cells of the kidneys, is derived from a larger precursor, prorenin. Plasma prorenin activity is increased in patients with insulin-dependent (Type I) diabetes mellitus who have microvascular complications of their disease. We undertook this study to determine prospectively whether rising prorenin activity can predict the development of complications in young patients with Type I diabetes. METHODS AND
RESULTS: Plasma prorenin was measured in 135 children and adolescents with Type I diabetes. The mean (+/- SE) plasma prorenin activity among the 32 patients over the age of 10 years who had had uncomplicated diabetes for 0.1 to 5 years was 8.43 +/- 0.58 ng of angiotensin I per liter.second, as compared with 7.06 +/- 0.32 in 37 control subjects of the same age (P less than 0.05). In the 9 patients older than 10 who had retinopathy or overt albuminuria, the mean plasma prorenin activity was 13.09 +/- 1.43 ng of angiotensin I per liter.second (P less than 0.0001). In 34 patients 10 years old or older with uncomplicated diabetes, 3 to 13 measurements of plasma prorenin activity were taken during a follow-up period of 6 to 39 months. Urinary albumin was determined at each visit, and the patients had regular retinal examinations. Only 1 of the 20 patients who had consistently normal plasma prorenin values had overt albuminuria (ratio of urinary albumin to creatinine, greater than 0.017) or retinopathy, whereas one or both of these complications appeared in 8 of the 14 who had at least one high prorenin value. The plasma prorenin value was significantly higher in these eight patients at least 18 months before a complication was found.
CONCLUSIONS: Increased plasma prorenin activity identifies a group of young patients with diabetes who are at high risk for retinopathy or nephropathy.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2215578     DOI: 10.1056/NEJM199010183231604

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  24 in total

Review 1.  Dual renin-angiotensin-aldosterone system blockade for diabetic kidney disease.

Authors:  Raimund H Pichler; Ian H de Boer
Journal:  Curr Diab Rep       Date:  2010-08       Impact factor: 4.810

Review 2.  Processing and sorting of human prorenin.

Authors:  W A Hsueh; Y S Do; P H Wang
Journal:  Cell Biophys       Date:  1991 Oct-Dec

3.  A brief history of renin.

Authors:  Friedrich C Luft
Journal:  J Mol Med (Berl)       Date:  2008-06       Impact factor: 4.599

Review 4.  Direct renin inhibition and the kidney.

Authors:  Norman K Hollenberg
Journal:  Nat Rev Nephrol       Date:  2009-11-24       Impact factor: 28.314

5.  Podocyte COX-2 exacerbates diabetic nephropathy by increasing podocyte (pro)renin receptor expression.

Authors:  Huifang Cheng; Xiaofeng Fan; Gilbert W Moeckel; Raymond C Harris
Journal:  J Am Soc Nephrol       Date:  2011-07       Impact factor: 10.121

6.  High plasma prorenin in non diabetic siblings of non insulin-dependent diabetes mellitus patients.

Authors:  N Glorioso; C Troffa; G Tonolo; F Filigheddu; F Dettori; M Ciccarese; A Saller; A Soro; E Brocco; P Pinna-Parpaglia; F Mantero; P P Faronato; R Nosadini; M Maioli
Journal:  J Endocrinol Invest       Date:  1999-11       Impact factor: 4.256

7.  Vascular damage without hypertension in transgenic rats expressing prorenin exclusively in the liver.

Authors:  M Véniant; J Ménard; P Bruneval; S Morley; M F Gonzales; J Mullins
Journal:  J Clin Invest       Date:  1996-11-01       Impact factor: 14.808

8.  Expression of nitric oxide synthase in macula densa in streptozotocin diabetic rats.

Authors:  N Yagihashi; N Nishida; H G Seo; N Taniguchi; S Yagihashi
Journal:  Diabetologia       Date:  1996-07       Impact factor: 10.122

9.  Serum total renin, an independent marker of the activity and severity of retinopathy in patients with IDDM.

Authors:  S Mäkimattila; P Summanen; I Matinlauri; M Mäntysaari; A Schlenzka; M Aalto; K Irjala; H Yki-Järvinen
Journal:  Br J Ophthalmol       Date:  1998-08       Impact factor: 4.638

Review 10.  Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors.

Authors:  Eduardo Pimenta; Suzanne Oparil
Journal:  Vasc Health Risk Manag       Date:  2009
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.